<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.4.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art540.dtd?><?SourceDTD.Version 5.4.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 2?><?origin publisher?><?FILEmeta_EBIOM751 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><?FILEgr7 jpg ?><?FILEmmc1 xlsx ?><?FILEmmc2 xlsx ?><?FILEmmc3 xlsx ?><?FILEsi1 gif ?><front><journal-meta><journal-id journal-id-type="nlm-ta">EBioMedicine</journal-id><journal-id journal-id-type="iso-abbrev">EBioMedicine</journal-id><journal-title-group><journal-title>EBioMedicine</journal-title></journal-title-group><issn pub-type="epub">2352-3964</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5049997</article-id><article-id pub-id-type="publisher-id">S2352-3964(16)30378-4</article-id><article-id pub-id-type="doi">10.1016/j.ebiom.2016.08.029</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Chemotherapy and Stem Cell Transplantation Increase <italic>p16</italic><sup><italic>INK4a</italic></sup> Expression, a Biomarker of T-cell Aging</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wood</surname><given-names>William A.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Krishnamurthy</surname><given-names>Janakiraman</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Mitin</surname><given-names>Natalia</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Torrice</surname><given-names>Chad</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Parker</surname><given-names>Joel S.</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Snavely</surname><given-names>Anna C.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Shea</surname><given-names>Thomas C.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Serody</surname><given-names>Jonathan S.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Sharpless</surname><given-names>Norman E.</given-names></name><email>NES@med.unc.edu</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="af0005"><label>a</label>Department of Medicine, The Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC, USA</aff><aff id="af0010"><label>b</label>Department of Genetics, The Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC, USA</aff><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: The Lineberger Comprehensive Cancer Center, CB #7295, Departments of Medicine and Genetics, The University of North Carolina School of Medicine, Chapel Hill, NC 27599-7295, USA.The Lineberger Comprehensive Cancer CenterDepartments of Medicine and GeneticsThe University of North Carolina School of MedicineCB #7295Chapel HillNC27599-7295USA <email>NES@med.unc.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>21</day><month>8</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>9</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>21</day><month>8</month><year>2016</year></pub-date><volume>11</volume><fpage>227</fpage><lpage>238</lpage><history><date date-type="received"><day>12</day><month>3</month><year>2016</year></date><date date-type="rev-recd"><day>16</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 The Authors</copyright-statement><copyright-year>2016</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="ab0005"><p>The expression of markers of cellular senescence increases exponentially in multiple tissues with aging. Age-related physiological changes may contribute to adverse outcomes in cancer survivors. To investigate the impact of high dose chemotherapy and stem cell transplantation on senescence markers in vivo, we collected blood and clinical data from a cohort of 63 patients undergoing hematopoietic cell transplantation. The expression of <italic>p16</italic><sup><italic>INK4a</italic></sup>, a well-established senescence marker, was determined in T-cells before and 6&#x000a0;months after transplant. RNA sequencing was performed on paired samples from 8 patients pre- and post-cancer therapy. In patients undergoing allogeneic transplant, higher pre-transplant <italic>p16</italic><sup><italic>INK4a</italic></sup> expression was associated with a greater number of prior cycles of chemotherapy received (p&#x000a0;=&#x000a0;0.003), prior autologous transplantation (p&#x000a0;=&#x000a0;0.01) and prior exposure to alkylating agents (p&#x000a0;=&#x000a0;0.01). Transplantation was associated with a marked increase in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression 6&#x000a0;months following transplantation. Patients receiving autologous transplant experienced a larger increase in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression (3.1-fold increase, p&#x000a0;=&#x000a0;0.002) than allogeneic transplant recipients (1.9-fold increase, p&#x000a0;=&#x000a0;0.0004). RNA sequencing of T-cells pre- and post- autologous transplant or cytotoxic chemotherapy demonstrated increased expression of transcripts associated with cellular senescence and physiological aging. Cytotoxic chemotherapy, especially alkylating agents, and stem cell transplantation strongly accelerate expression of a biomarker of molecular aging in T-cells.</p></abstract><abstract abstract-type="author-highlights" id="ab0010"><title>Highlights</title><p><list list-type="simple"><list-item id="u0005"><label>&#x02022;</label><p>Peripheral blood T-cell senescence, as measured by the marker <italic>p16</italic><sup><italic>INK4a</italic></sup>, increases following autologous or allogeneic HSCT.</p></list-item><list-item id="u0010"><label>&#x02022;</label><p>RNAseq of T-cells post- auto HSCT or chemotherapy show increased expression of transcripts associated with senescence.</p></list-item><list-item id="u1105"><label>&#x02022;</label><p>Autologous HCT in particular induces a stronger effect on Tcell <italic>p16<sup>INK4a</sup></italic> expression than any other environmental stimulus tested to date.</p></list-item></list></p><p>Human chronological aging is associated with increased expression of markers of cellular aging (senescence). Cancer chemotherapy can produce frailty syndromes &#x02013; recipients of cancer treatment may experience physiological changes ordinarily seen in individuals of more advanced chronological age. In our study, we found that a well-known marker of cellular senescence, <italic>p16</italic><sup><italic>INK4a</italic></sup>, increased in patients following autologous or allogeneic hematopoietic cell transplantation. Expression of <italic>p16</italic><sup><italic>INK4a</italic></sup> was higher in patients exposed to greater amounts of chemotherapy before transplant and those exposed to specific types of chemotherapy. These findings may ultimately influence clinical decision-making for patients with diseases that are commonly treated with transplantation.</p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>Aging</kwd><kwd>Senescence</kwd><kwd>Exhaustion</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p>Hematopoietic stem cell transplantation (HSCT) is a potentially curative modality for high-risk hematologic diseases, but the procedure has profound and long-term effects on recipient hematologic and immune function. The long-term toxicity of HSCT may result from chemo-radiotherapy given at the time of transplantation (conditioning), from donor-host immune differences after allogeneic transplants or from accelerated stem cell exhaustion of transplanted stem cells (<xref rid="bb0095" ref-type="bibr">Hake et al., 2007</xref>). These late toxicities manifest as increased risk for infection, chronic graft-vs-host disease, bone marrow failure and acute leukemia.</p><p>Recent evidence has demonstrated that peripheral blood T-cells express markers of cellular senescence with physiological aging. The overall loss of physiological reserve that accompanies aging is associated with an accumulation of senescent cells (<xref rid="bb0255" ref-type="bibr">Sharpless and Depinho, 2007</xref>, <xref rid="bb0235" ref-type="bibr">Rodier and Campisi, 2011</xref>). Cellular senescence is triggered by activation of tumor suppressor mechanisms associated with cellular stressors, and results in expression of the <italic>p16</italic><sup><italic>INK4a</italic></sup> tumor suppressor protein encoded by the <italic>CDKN2a</italic> locus, which has emerged as one of the more useful markers of senescence in vivo (<xref rid="bb0040" ref-type="bibr">Campisi, 2013</xref>, <xref rid="bb0260" ref-type="bibr">Sharpless and Sherr, 2015</xref>). Expression of <italic>p16</italic><sup><italic>INK4a</italic></sup> in peripheral blood T lymphocytes increases exponentially with chronological age, doubling about every decade (<xref rid="bb0305" ref-type="bibr">Zindy et al., 1997</xref>, <xref rid="bb0140" ref-type="bibr">Krishnamurthy et al., 2004</xref>, <xref rid="bb0175" ref-type="bibr">Liu et al., 2009</xref>). Polymorphisms of senescence regulators have been associated with age-related conditions such as cancer, pulmonary fibrosis, glaucoma, atherosclerosis, and type II diabetes (<xref rid="bb0130" ref-type="bibr">Jeck et al., 2012</xref>, <xref rid="bb0265" ref-type="bibr">Siegel et al., 2012</xref>). Prior work has shown that several age-promoting stressors such as smoking, physical inactivity and chronic HIV infection accelerate the expression of <italic>p16</italic><sup><italic>INK4a</italic></sup> and other markers of cellular senescence (<xref rid="bb0175" ref-type="bibr">Liu et al., 2009</xref>, <xref rid="bb0210" ref-type="bibr">Nelson et al., 2012</xref>). Importantly, we recently showed that cytotoxic chemotherapy, given in the adjuvant setting, markedly increases expression of senescence markers in the peripheral blood, consistent with ~&#x000a0;15&#x000a0;years of chronological aging (<xref rid="bb0245" ref-type="bibr">Sanoff et al., 2014</xref>).</p><p>Increasingly, older individuals are considered for autologous or allogeneic transplantation. While age itself is usually not considered an absolute contraindication to transplantation, older individuals do have higher risks of acute transplant-related toxicities such as cardiac arrhythmias, diarrhea and mucositis (<xref rid="bb0295" ref-type="bibr">Wildes et al., 2014</xref>). Further, age-related comorbid illness is itself prognostic for outcomes in autologous and allogeneic transplant recipients, suggesting that functional, if not chronological, age of prospective transplant candidates is a potentially important variable for clinical decision-making. Lastly, survivors of transplants, regardless of age, are at risk for accelerated acquisition of several age-related syndromes such as endocrine dysfunction, cognitive impairment, cardiovascular morbidity, immune dysfunction, secondary neoplasms, and neuromuscular impairment (<xref rid="bb0080" ref-type="bibr">Fried et al., 2001</xref>).</p><p>In murine models, serial transplantation per se, in the absence of exposure to cytotoxic agents, is associated with accelerated aging of hematopoietic stem cells (HSC), manifesting as &#x02018;HSC exhaustion&#x02019; (<xref rid="bb0110" ref-type="bibr">Harrison and Astle, 1982</xref>). Likewise, evidence suggests HSC exhaustion occurs in humans as well. HSC yields for autologous transplant from patients that have undergone significant prior chemotherapy are significantly depressed compared to yields from less heavily treated individuals (<xref rid="bb0055" ref-type="bibr">Clark and Brammer, 1998</xref>), and the transplantation of insufficient numbers of HSC is associated with long term graft failure (<xref rid="bb0215" ref-type="bibr">Perez-Simon et al., 1999</xref>). Additionally, transplantation is associated with an increased rate of telomere shortening, which has been associated with certain adverse outcomes in transplant recipients (<xref rid="bb0150" ref-type="bibr">Lee et al., 1999</xref>, <xref rid="bb0160" ref-type="bibr">Lewis et al., 2004</xref>, <xref rid="bb0015" ref-type="bibr">Akiyama et al., 2000</xref>, <xref rid="bb0225" ref-type="bibr">Pipes et al., 2006</xref>). Because individuals with hematologic malignancies have an increasing array of transplant approaches of varying intensity as well as non-transplant treatment approaches available to them, understanding the impact of treatment upon functional aging may have important implications for the care of both prospective transplant candidates as well as transplant survivors. Toward that end, we measured expression of <italic>p16</italic><sup><italic>INK4a</italic></sup>, a marker of molecular age that can be serially assessed, in HSC-derived T-cells before and after stem cell transplantation. Additionally, we performed whole transcriptomic RNA sequencing in a subset of paired samples to further examine the effects of chemotherapy or transplantation on T-cell function.</p></sec><sec id="s0010"><label>2</label><title>Materials and Methods</title><sec id="s0015"><label>2.1</label><title>Patients</title><p>For the transplant patient population, participants were over the age of 18 and underwent either autologous or allogeneic stem cell transplantation for any hematologic malignancy between 2010 and 2013 at the University of North Carolina (UNC) Hospitals. Patient samples were obtained from two non-randomized, non-blinded observational cohorts: a study investigating symptom burden after transplantation, and a generic tissue procurement protocol. Studies were approved by the UNC Institutional Review Board (11&#x02013;0600 and 13&#x02013;1705), with study procedures confirming to standards indicated by the Declaration of Helsinki. Eligible patients were identified from the electronic medical records and approached by research personnel prior to scheduled transplantation for provision of signed informed consent. Patients undergoing concurrent radiation, chemotherapeutic, or investigational therapy other than transplant-related therapy were excluded. All patients received standard-of-care therapies and treatments as clinically needed. Medical history and treatment information were abstracted from the medical record. Samples were obtained in both cohorts from just before transplantation, and paired samples from 6&#x000a0;months post-transplantation were also obtained if available. Molecular analyses were performed by investigators blinded to patient data, and investigators collecting clinical information were blinded to laboratory results until data collection was complete. For the breast cancer patient population, T-cell RNA collected in the study Sanoff et al. (<xref rid="bb0245" ref-type="bibr">Sanoff et al., 2014</xref>) was used in the RNA sequencing analysis.</p></sec><sec id="s0020"><label>2.2</label><title>Assessment of <italic>p16</italic><sup><italic>INK4a</italic></sup> expression</title><p>See Sanoff et al. (<xref rid="bb0245" ref-type="bibr">Sanoff et al., 2014</xref>) for details. In brief, CD3<sup>+</sup> T-cells were isolated from up to 10-ml of peripheral blood using anti-CD3 microbeads and an AutoMACS<sup>PRO</sup> separator (Miltenyi Biotec, San Diego, CA). Purity of T cells was determined to be ~&#x000a0;95% when isolated from fresh blood and ~&#x000a0;50% when isolated from cryopreserved PBMCs in pilot experiments. T cell purity in clinical trial samples was monitored by measuring expression of the gamma subunit of the <italic>CD3</italic>. Total RNA was isolated using RNeasy Mini Kit (Qiagen) and cDNA were prepared using ImProm-II reverse transcriptase kit (Promega). Expression of <italic>p16</italic><sup><italic>INK4a</italic></sup> was measured by TaqMan quantitative reverse-transcription polymerase chain reaction specific for <italic>p16</italic><sup><italic>INK4a</italic></sup> and normalized to <italic>YWHAZ</italic> housekeeping gene (<xref rid="bb0185" ref-type="bibr">Mane et al., 2008</xref>, <xref rid="bb0065" ref-type="bibr">Dheda et al., 2004</xref>).</p></sec><sec id="s0025"><label>2.3</label><title>RNA Sequencing</title><p>RNA was extracted and rRNA was removed using the Ribo-Zero kit. RNA libraries were prepared by using the Illumina TruSeq RNA Sample Preparation Kit v2 and then sequenced by Illumina HiSeq2000. Reads were subjected to quality control as previously described (<xref rid="bb0045" ref-type="bibr">Cancer Genome Atlas Research, 2012</xref>). RNA reads were aligned to human hg19 genome assembly using Mapsplice (<xref rid="bb0290" ref-type="bibr">Wang et al., 2010</xref>). Gene definitions were obtained from the UCSC known Gene table. Gene expression was estimated using RSEM (RNA-Seq by Expectation Maximization) (<xref rid="bb0165" ref-type="bibr">Li and Dewey, 2011</xref>). Genes differentially expressed due to treatment were identified by DESeq2 (<xref rid="bb0180" ref-type="bibr">Love et al., 2014</xref>) using a bivariate model to adjust for subject specific effects. The resulting statistics were subjected to gene set enrichment analysis by using the GSEA (Gene Set Enrichment Analysis) rank test (<xref rid="bb0275" ref-type="bibr">Subramanian et al., 2005</xref>). Expression estimates were normalized to a fixed upper quartile and log2 transformed prior to visualization.</p></sec><sec id="s0030"><label>2.4</label><title>Statistical Analyses</title><p>The sample size was determined by the availability of clinical specimens from the two study cohorts as described. Log<sub>2</sub>-transformed <italic>p16</italic><sup><italic>INK4a</italic></sup> expression values were standardized through conversion to <italic>Z</italic>-score to facilitate combining the two sample sets. Z-scores were calculated separately for the two transplant cohorts using the formula:<disp-formula id="fo0005"><mml:math id="M1" altimg="si1.gif" overflow="scroll"><mml:msub><mml:mi mathvariant="normal">Z</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfenced open="(" close=")" separators=","><mml:mrow><mml:msub><mml:mi mathvariant="normal">X</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">&#x003bc;</mml:mi></mml:mrow></mml:mfenced><mml:mo stretchy="true">/</mml:mo><mml:mi mathvariant="normal">&#x003c3;</mml:mi></mml:math></disp-formula>where &#x003bc; is population mean, and &#x003c3; is standard deviation.</p><p>For samples present in both cohorts, individual Z scores were averaged. Associations between <italic>p16</italic><sup><italic>INK4a</italic></sup> expression and pre-transplant variables were performed using linear regression (for continuous variables) or one-way analysis of variance (for categorical variables). A paired <italic>t</italic>-test was used to compare <italic>p16</italic><sup><italic>INK4a</italic></sup> expression before and after transplant. Data were analyzed by N. Mitin using JMP11 (SAS, Cary, NC) and A. Snavely using R. All tests of statistical significance were two-sided. <italic>P</italic> values of 0.05 or less were considered statistically significant.</p></sec></sec><sec id="s0035"><label>3</label><title>Results</title><p>Two observational cohorts (<xref rid="t0005" ref-type="table">Table 1</xref>) were combined for our analysis, and the baseline characteristics of the aggregated cohort are shown in <xref rid="t0010" ref-type="table">Table 2</xref>. In order to compare samples analyzed from the two observational cohorts, we converted all <italic>p16</italic><sup><italic>INK4a</italic></sup> expression values to a normalized <italic>Z</italic>-score as described in the methods. Using this conversion, we found excellent correlation among Z-scores for the 17 patients that had separate samples obtained in both cohorts (<xref rid="t0015" ref-type="table">Table 3</xref>), suggesting the aggregation of the observational cohorts for analysis is valid. In the combined cohort there were 26 unique patients who underwent autologous transplantation and 37 who underwent allogeneic transplantation, for a total of 63 unique patients (<xref rid="t0010" ref-type="table">Table 2</xref>). A majority of autologous transplant recipients had myeloma, and the rest had lymphoma as an underlying diagnosis. Most allogeneic transplant recipients had leukemia as their underlying diagnosis. Five allogeneic transplant recipients had previously undergone autologous transplantation.</p><p>Among autologous HSCT recipients, there were no baseline characteristics that were associated with pre-transplant <italic>p16</italic><sup><italic>INK4a</italic></sup> expression. Among allogeneic HSCT recipients, however, a greater number of cycles of chemotherapy received before allogeneic transplant, history of prior autologous transplantation, and history of alkylating agent exposure were all significantly associated with higher pre-transplant <italic>p16</italic><sup><italic>INK4a</italic></sup> expression (p&#x000a0;&#x0003c;&#x000a0;0.01 for each, <xref rid="t0020" ref-type="table">Table 4</xref>A and B). In accord with results in patients treated with chemotherapy for breast cancer (<xref rid="bb0245" ref-type="bibr">Sanoff et al., 2014</xref>), prior exposure to alkylating agents was associated with a 1.9-fold increase in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression (absolute value, log2&#x000a0;=&#x000a0;0.91). Moreover, there was a 2.3-fold increase in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression level (absolute value, log2&#x000a0;=&#x000a0;1.22) in the small number of allogeneic patients that had undergone prior autologous transplant. Previously, we have shown that a 2-fold increase in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression is equivalent to ~&#x000a0;10&#x000a0;years of chronological aging (<xref rid="bb0245" ref-type="bibr">Sanoff et al., 2014</xref>). Therefore, these data suggest that extensive exposure to alkylating agents or autologous transplantation is equivalent in molecular terms to a chronological decade or more increase in the chronological age of Peripheral Blood T-Lymphocytes (PBTL).</p><p>Next, we determined the effects of HSCT on molecular age of PBTL as measured by <italic>p16</italic><sup><italic>INK4a</italic></sup> expression by comparing pre- and post-HSCT <italic>p16</italic><sup><italic>INK4a</italic></sup> levels within an individual. As shown in <xref rid="t0025" ref-type="table">Table 5</xref>, hematopoietic stem cell transplantation was associated with a significant increase in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression levels for both autologous and allogeneic transplant recipients. Allogeneic transplant recipients showed a pronounced increase in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression post-HSCT (1.93-fold, p&#x000a0;=&#x000a0;0.0004). In the allogeneic setting, the PBTL pre-HSCT were derived from the host, whereas the PBTL post-HSCT were largely if not entirely donor-derived (given near 100% chimerism in patients post-engraftment). Since the hosts, who generally were transplanted for AML, had experienced prior chemotherapy and, in a small number of cases, auto-HSCT, we would expect that the pre-HSCT levels of <italic>p16</italic><sup><italic>INK4a</italic></sup> would be considerably higher than the expression of <italic>p16</italic><sup><italic>INK4a</italic></sup> in their healthy donors. Therefore, the measured change in <italic>p16</italic><sup><italic>INK4a</italic></sup> from pre-HSCT to post-HSCT in allogeneic recipients likely underestimates the age-promoting effects on the graft of HSCT, given that the pre-HSCT levels were elevated in the recipients from prior therapeutic exposure. In the allogeneic HSCT setting, it is possible that other unaccounted factors (e.g. post-transplant calcineurin-inhibitor exposure) may have also contributed to the observed effect.</p><p>In order to directly measure the effects of human HSCT per se on molecular age, we turned to an analysis of patients undergoing autologous HSCT. In accord with our finding that autologous HSCT prior to allogeneic transplant was associated with elevated <italic>p16</italic><sup><italic>INK4a</italic></sup> in pooled patients (<xref rid="t0020" ref-type="table">Table 4</xref>), we noted that within any given patient, autologous HSCT was associated with a marked increase in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression from pre-transplant to 6&#x000a0;months post-transplant (3.05-fold, p&#x000a0;=&#x000a0;0.002). This finding suggests that the forced bone marrow repopulation associated with transplantation per se accelerates the molecular aging of PBTL, in the absence of significant chemotherapy exposure to the graft.</p><sec id="s0040"><label>3.1</label><title>Relationship of Transplantation and Chemotherapy with Peripheral Blood T-cell Gene Expression</title><p>To further understand the long-term effects of DNA damaging agents and HSCT on PBTL, we performed whole transcriptome RNA sequencing before and after cancer therapy. In order to identify transcriptional changes that were not specific to a particular noxious insult, but instead were induced by the generic insult of forced bone marrow regeneration, we performed an analysis of samples pre- and post-autologous transplantation (3 pairs of samples) or pre- and post-cytotoxic chemotherapy (5 pairs of samples). In order to focus on durable changes to the T-cell transcriptome, PBTL were collected 6&#x000a0;months post-autologous HSCT or 6&#x02013;12&#x000a0;months post-adjuvant chemotherapy with doxorubicin and cyclophosphamide for breast cancer (these samples are described in (<xref rid="bb0245" ref-type="bibr">Sanoff et al., 2014</xref>)). We performed whole transcriptome RNA sequencing of ribosome depleted total RNA on pre- and post-therapy T-cell samples, and compared expression profiles through pairwise supervised analysis. This approach identified a signature of ~&#x000a0;500 coding transcripts whose expression was significantly (adjusted p-value&#x000a0;&#x0003c;&#x000a0;0.05) and durably altered by these types of cancer therapy. If restricted to genes whose expression changed &#x0003e;&#x000a0;1.9-fold from baseline, we identified 134 coding transcripts that significantly increased in expression, and 47 transcripts that significantly decreased in expression (<xref rid="ec0005" ref-type="supplementary-material">Supp. Tables 1</xref>, 2), which are presented as a representative subset in <xref rid="f0005" ref-type="fig">Fig. 1</xref> and overall by hierarchical clustering in <xref rid="f0010" ref-type="fig">Fig. 2</xref>. These data demonstrate a potent and lasting effect on transcription of the T-cell organ after forced bone marrow regeneration.</p><p>In order to determine the effects of auto-transplant or chemotherapy on T-cell function, we performed several types of bioinformatic analysis on these RNA sequencing data. We used gene set enrichment analysis (GSEA) and supervised gene set analysis (SAM-GSA) to compare the genes altered by cancer therapy to ~&#x000a0;8000 known gene sets in the Molecular Signatures database (<xref rid="bb0275" ref-type="bibr">Subramanian et al., 2005</xref>). These analyses identified a large number of published signatures with significant overlap with our gene list, of which the vast majority (&#x0003e;&#x000a0;90%) were immunologic. Using an adjusted p-value of 0.05, 211 gene sets significantly overlapped with transcripts more highly expressed in the pre-therapy samples (<xref rid="ec0010" ref-type="supplementary-material">Supp. Table 3</xref>), and 98 overlapped with transcripts that were more highly expressed in the post-therapy samples (<xref rid="ec0015" ref-type="supplementary-material">Supp. Table 4</xref>). Hierarchical clustering of representative GSEA signatures are shown in <xref rid="f0015" ref-type="fig">Fig. 3</xref>, <xref rid="f0020" ref-type="fig">Fig. 4</xref>, <xref rid="f0025" ref-type="fig">Fig. 5</xref>, <xref rid="f0030" ref-type="fig">Fig. 6</xref>, <xref rid="f0035" ref-type="fig">Fig. 7</xref>. These GSEA results appear to be predominantly explained by changes in the composition of the CD3&#x000a0;+ fraction of lymphocytes post-cancer therapy. For example, transcripts that were more highly expressed in memory CD4&#x000a0;+ cells relative to na&#x000ef;ve cells increased after cancer therapy (<xref rid="f0015" ref-type="fig">Fig. 3</xref>), and the same was true for transcripts that were more highly expressed in effector memory compared to central memory CD4&#x000a0;+ cells (<xref rid="f0020" ref-type="fig">Fig. 4</xref>). Transcripts that were more highly expressed in regulatory T cells compared to conventional T cells also increased following cancer treatment (<xref rid="f0025" ref-type="fig">Fig. 5</xref>). As shifts from central memory and na&#x000ef;ve cells to effector cells and Tregs are hallmark changes of peripheral T-cells with aging (<xref rid="bb0060" ref-type="bibr">Desai et al., 2010</xref>), these data provide further evidence that cancer therapy accelerates the changes in T-cell subsets that are associated with aging of the cellular immune system.</p><p>An analysis of specific genes altered by cancer therapy was also illuminating (selected transcripts are clustered in <xref rid="f0005" ref-type="fig">Fig. 1</xref>). For example, we observed a robust increase in transcripts associated generally with cellular senescence (e.g. <italic>CDKN2a</italic>, <italic>IL8</italic>, <italic>HMGA2</italic>, <italic>CCL4</italic>) (<xref rid="bb0205" ref-type="bibr">Narita et al., 2006</xref>, <xref rid="bb0005" ref-type="bibr">Acosta et al., 2008</xref>, <xref rid="bb0100" ref-type="bibr">Hammond and Sharpless, 2008</xref>, <xref rid="bb0050" ref-type="bibr">Cheng et al., 2015</xref>) or telomere shortening in T-cells (e.g. <italic>KLRK1</italic>, <italic>NUAK1</italic>, <italic>DSP</italic>, <italic>PIF1</italic>) (<xref rid="bb0115" ref-type="bibr">Humbert et al., 2010</xref>, <xref rid="bb0270" ref-type="bibr">Soriani et al., 2014</xref>, <xref rid="bb0285" ref-type="bibr">Textor et al., 2011</xref>, <xref rid="bb0145" ref-type="bibr">Lansdorp, 2007</xref>, <xref rid="bb0230" ref-type="bibr">Robin et al., 2014</xref>). Additionally, we noted changes that have been previously associated with T-cell aging and immunosenescence: decreased <italic>CD28</italic> expression (<xref rid="bb0075" ref-type="bibr">Effros et al., 1994</xref>) and increased expression of several NK markers (e.g. <italic>CX3CR1</italic>, <italic>KLRK1</italic>, <italic>KLRA1</italic>) (<xref rid="bb0090" ref-type="bibr">Goronzy and Weyand, 2005</xref>, <xref rid="bb0250" ref-type="bibr">Sciume et al., 2011</xref>, <xref rid="bb0025" ref-type="bibr">Bauer et al., 1999</xref>, <xref rid="bb0035" ref-type="bibr">Bull et al., 2000</xref>). Consistent with the GSEA results and known patterns of human T-cell aging, there was a relative depletion of transcripts associated with central memory cells with an enrichment of transcripts associated with effector CD8&#x000a0;+ T-cells (e.g. decreased <italic>CCR7</italic> and <italic>IL7R&#x003b1;</italic>, with increased <italic>GZMB</italic>, <italic>CD8a</italic> and NK markers (<xref rid="f0005" ref-type="fig">Fig. 1</xref>)). In accord with these processes, we observed that cancer therapy induced the expression of transcripts that are more highly expressed in T-cells from old versus young donors (<xref rid="f0030" ref-type="fig">Fig. 6</xref>). The effects on transcripts associated with T-cell exhaustion were less consistent: a few well-recognized markers of exhaustion significantly increased post-bone marrow insult (e.g. CD160 and LAG3, <xref rid="f0005" ref-type="fig">Fig. 1</xref>), whereas published signatures of T-cell exhaustion demonstrated a mixed pattern of expression in GSEA analysis (<xref rid="f0035" ref-type="fig">Fig. 7</xref>, see also Tables 8 and 9). These gene-specific data provide evidence beyond changes to <italic>p16</italic><sup><italic>INK4a</italic></sup> (<xref rid="t0010" ref-type="table">Table 2</xref>) that generic types of hematopoietic injury (e.g. forced bone marrow repopulation, cytotoxic chemotherapy) induces durable transcriptional changes characteristic of T-cell aging and immunosenescence, suggesting these insults accelerate T-cell molecular aging.</p></sec></sec><sec id="s0045"><label>4</label><title>Discussion</title><p>In this work, we show that that DNA damaging chemotherapy and stem cell transplantation potently induce the transcriptional changes characteristic of aging in PBTL. This includes both changes associated with an altered composition of the T-cell organ with aging (e.g. decreased na&#x000ef;ve and central memory cells versus increased effector memory cells and Tregs) as well as changes associated with telomere shortening and cellular senescence. While the notion that DNA damaging agents induce cellular senescence in vivo is non-controversial, a remarkable aspect of this work is the finding that autologous HSCT markedly induces the transcriptional changes of PBTL aging. For example, auto-HSCT increases the expression of <italic>p16</italic><sup><italic>INK4a</italic></sup>, a highly dynamic marker of senescence, to a degree comparable ~&#x000a0;30&#x000a0;years of chronological age. A similar increase in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression with auto-HSCT has been reported in myeloma patients (<xref rid="bb0240" ref-type="bibr">Rosko et al., 2015</xref>). As the autograft is not exposed to DNA damaging chemotherapy, this observation suggests that the forced proliferation that accompanies BM re-engraftment, even in the absence of exogenous clastogens, may be age-promoting in humans.</p><p>In accord with prior work (<xref rid="bb0245" ref-type="bibr">Sanoff et al., 2014</xref>), we observed relatively increased expression of PBTL <italic>p16</italic><sup><italic>INK4a</italic></sup> in pre-treatment samples from patients undergoing allogeneic, but not autologous stem cell transplant. This observation likely reflects differences in prior therapy between these two patient groups: with allogeneic HSCT patients having received high doses of alkylating agents and anthracyclines for acute leukemia, whereas autologous patients received largely non-cytotoxic anti-myeloma therapies such as bortezomib and lenalidomide. This observation suggests that cytotoxic chemotherapy may be more age-promoting than non-cytotoxic drugs used for myeloma, and is consonant with the practice of avoiding alkylating agents in patients with myeloma because such drugs impair subsequent stem cell collection (<xref rid="bb0055" ref-type="bibr">Clark and Brammer, 1998</xref>).</p><p>It is perhaps surprising that autologous HSCT induces the strongest effect on PBTL molecular age, as measured by <italic>p16</italic><sup><italic>INK4a</italic></sup> expression, of any noxious stimulus to date tested, including cytotoxic chemotherapy (<xref rid="bb0245" ref-type="bibr">Sanoff et al., 2014</xref>), chronic HIV infection (<xref rid="bb0210" ref-type="bibr">Nelson et al., 2012</xref>), tobacco use (<xref rid="bb0175" ref-type="bibr">Liu et al., 2009</xref>) or physical inactivity (<xref rid="bb0175" ref-type="bibr">Liu et al., 2009</xref>). We believe the most likely explanation for this finding is that the forced BM regeneration that accompanies re-engraftment induces intrinsic HSC aging. Serial transplant readily &#x02018;exhausts&#x02019; HSC in murine models (<xref rid="bb0105" ref-type="bibr">Harrison, 1979</xref>), leading to a &#x02018;myeloid skewing&#x02019; characterized by a marked decline in the per HSC capacity to produce na&#x000ef;ve T-cells (<xref rid="bb0120" ref-type="bibr">Janzen et al., 2006</xref>), an observation that is in accord with our RNAseq analysis (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). Furthermore, though pre-treatment samples from patients undergoing allogeneic HSCT had higher PBTL <italic>p16</italic><sup><italic>INK4a</italic></sup> expression than those from patients undergoing autologous HSCT, it is possible that pre-transplant therapy had some age-promoting effect upon PBTLs in autologous HSCT recipients. Thus, in combination with forced BM regeneration, PBTLs of autologous HSCT recipients were &#x0201c;aged&#x0201d; twice due to therapy and then transplant, possibly helping to explain the larger effect on PBTL <italic>p16</italic><sup><italic>INK4a</italic></sup> expression from autologous in comparison with allogeneic HSCT.</p><p>Beyond an effect on HSC, however, it is possible that damage to other tissues contributes to this effect. For example, the thymus is damaged by pre-transplant conditioning with high-dose chemotherapy, and it is likely that graft-derived T-cells produced via a dysfunctional thymus exhibit accelerated aging (<xref rid="bb0195" ref-type="bibr">Min et al., 2005</xref>, <xref rid="bb0200" ref-type="bibr">Montecino-Rodriguez et al., 2013</xref>, <xref rid="bb0070" ref-type="bibr">Dorshkind et al., 2009</xref>, <xref rid="bb0170" ref-type="bibr">Linton and Dorshkind, 2004</xref>). Moreover, it is possible that not all host hematopoietic stem cells and self-renewing T-cells are destroyed by the conditioning regimen, and these surviving cells could exhibit accelerated aging as a result of exposure to conditioning. Since our analysis is performed on pooled PBTL, even a rare population of surviving cells that highly express <italic>p16</italic><sup><italic>INK4a</italic></sup> could affect a post-transplant sample's results. While such effects could affect PBTL <italic>p16</italic><sup><italic>INK4</italic></sup>, it is unlikely that thymic damage or very rare surviving host T-cells would cause the wholesale transcriptional effects observed in the RNAseq analysis.</p><p>Our finding that post-transplant senescent T-cells were biased toward the expression of transcripts associated with CD8&#x000a0;+ effector cells and NK cells is consistent with prior studies of T-cell aging and immunosenescence. (<xref rid="bb0220" ref-type="bibr">Perillo et al., 1993</xref>, <xref rid="bb0125" ref-type="bibr">Jaruga et al., 2000</xref>, <xref rid="bb0155" ref-type="bibr">Lemster et al., 2008</xref>). In aggregate, our work and other studies suggest that noxious stimuli such as DNA damage, telomere shortening and forced regeneration mimic the effects of chronologic age to augment the production of hypo-replicative T-cells with distinct immunophenotype (e.g. CD8&#x000a0;+&#x000a0;CD28-) that express effector molecules such as Granzyme B and NK markers as well as markers of cellular senescence (e.g. <italic>p16</italic><sup><italic>INK4a</italic></sup> and IL8). Such senescence-promoting stimuli have a more complex effect on markers of T-cell exhaustion, leading to increased expression of some exhaustion-associated markers and decreased expression of others. This finding is in accord with the notion that there are at least two different types of severely hyporeplicative states induced by excess T-cell proliferation&#x02014;cellular senescence and exhaustion (<xref rid="bb0010" ref-type="bibr">Akbar and Henson, 2011</xref>)&#x02014;with our work suggesting forced replication and DNA damaging agents induce the former, but not the latter, in humans.</p><p>This work has several implications. First, it is possible that an assessment of T-cell molecular age could be used to predict suitability for transplantation. In fact, prior studies have shown that older autologous HSCT recipients have a higher likelihood than younger recipients of failing to achieve complete peripheral blood count recovery at 1&#x000a0;year, particularly true in patients who have been exposed to prior cytotoxic chemotherapy (<xref rid="bb0300" ref-type="bibr">Woolthuis et al., 2014</xref>, <xref rid="bb0030" ref-type="bibr">Bhatia et al., 2005</xref>). Such a use would be similar to the suggestion that a renal allograft's molecular age, as measured by <italic>p16</italic><sup><italic>INK4a</italic></sup> expression, is a stronger predictor of long-term graft function than donor age or telomere length (<xref rid="bb0135" ref-type="bibr">Koppelstaetter et al., 2008</xref>, <xref rid="bb0190" ref-type="bibr">Mcglynn et al., 2009</xref>, <xref rid="bb0085" ref-type="bibr">Gingell-Littlejohn et al., 2013</xref>). Larger studies with longer follow-up would be needed to confirm the hypothesis that donor molecular age of HSC influences long-term hematopoietic graft function. Second, post-transplant T-cell senescence may have important implications with regard to T-cell function, with an increase in the frequency of senescent T-cells leading to greater long-term risk of infection or decreased response to vaccination (<xref rid="bb0280" ref-type="bibr">Targonski et al., 2007</xref>). Additionally, if increased molecular age of PBTL is the result of intrinsic HSC aging, this marker could also perhaps predict other late complications of HSCT such as bone marrow failure, MDS or secondary leukemia. Third, the finding that HSCT and DNA damaging agents promote the molecular aging of T-cells suggests such agents may compromise the post-transplant ability to respond to therapies intended to activate exhausted T-cells (e.g. anti-PD1 antibodies). Finally, the significant increase in T-cell senescence after HSCT further raises questions about the potential long term risks related to accelerated aging in recipients of two transplants (e.g. tandem autologous transplantation). For diseases in which credible non-transplant treatment approaches exist, pre-transplant &#x0201c;molecular age&#x0201d; and subsequent risk for further transplant-related accelerated aging could impact clinical decision-making.</p><p>We acknowledge limitations to our work. First, we did not have data to demonstrate a correlation between the observed changes in biomarker expression with T cell function. However, inasmuch as <italic>p16</italic><sup><italic>INK4a</italic></sup> expression is arguably one of the best in vivo markers of cellular senescence and is directly associated with age-related deterioration (<xref rid="bb0020" ref-type="bibr">Baker et al., 2016</xref>), the signal of increased senescence early after transplantation is clear and concerning, even if a clearer explanation of this phenomena requires further study. Second, other aspects of post-transplant immune reconstitution also influence the relative contribution of CD8 and CD4 T cells to the CD3 population in the early post-transplant period. Third, the relative contribution of clinical factors to PBTL <italic>p16</italic><sup><italic>INK4a</italic></sup> expression, including graft versus host disease, infection, and use of immunosuppressive agents, could not be discerned in this analysis. Fourth, we did not have sequential longitudinal post-transplant samples available to study changes in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression over time. Fifth, donor samples were limited. We were unable in this study to determine the source of the T cells that were undergoing changes in biomarker expression following allogeneic transplantation; a clear idea of which cells were donor-derived and which were recipient-derived would help to discern the relative effects of chemotherapy vs transplant upon <italic>p16</italic><sup><italic>INK4a</italic></sup> expression.</p><p>In summary, we have shown that HSCT and cancer therapy strongly increase the expression in T cells of <italic>p16</italic><sup><italic>INK4a</italic></sup>, a well-known biomarker of cellular senescence. Further, this likely occurs via an effect on hematopoietic stem cells. <italic>p16</italic><sup><italic>INK4a</italic></sup> expression was markedly increased following transplantation, and in association with amount and certain types of chemotherapy. This observation may have implications for the management of patients with cancer as well as cancer survivors, in order to limit pro-aging effects of treatment and to protect against the development of frailty and other aging-related syndromes. Additional studies to investigate the relationships between T-cell aging and adverse outcomes following cancer therapy are warranted.</p><p>The following are the supplementary data related to this article.<supplementary-material content-type="local-data" id="ec0005"><caption><title>Supplementary Table 1</title><p>Coding transcripts with <underline>increased</underline> expression post-cancer therapy. All transcripts are significantly changed (adjusted p-value&#x000a0;&#x0003c;&#x000a0;0.05) &#x0003e;&#x000a0;1.9-fold.</p><p>Supplementary Table 2 Coding transcripts with <underline>decreased</underline> expression post-cancer therapy. All transcripts are significantly changed (adjusted p-value&#x000a0;&#x0003c;&#x000a0;0.05) &#x0003e;&#x000a0;1.9-fold.</p></caption><media xlink:href="mmc1.xlsx"><alt-text>Supplementary Table 1</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="ec0010"><caption><title>Supplementary Table 3</title><p>GSEA signatures that significantly overlap with transcripts that are more highly expressed before cancer therapy.</p></caption><media xlink:href="mmc2.xlsx"><alt-text>Supplementary Table 3</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="ec0015"><caption><title>Supplementary Table 4</title><p>GSEA signatures that significantly overlap with transcripts that are more highly expressed after cancer therapy.</p></caption><media xlink:href="mmc3.xlsx"><alt-text>Supplementary Table 4</alt-text></media></supplementary-material></p></sec><sec id="s0050"><title>Funding Sources</title><p>This work was supported by <funding-source id="gts0005">NIH</funding-source> grant 2 R01 AG024379 11A1, The Role of <italic>p16</italic><sup><italic>INK4</italic></sup> in Mammalian Aging, PI Norman Sharpless. The funder has no role in data collection or analysis in this research.</p></sec><sec id="s0055"><title>Conflict of Interest Statement</title><p>N.M. and N.E.S. are founders and hold equity in HealthSpan Diagnostics, which is developing clinical grade assays for molecular aging related to this work. K.J. and N.E.S. are inventors on an issued patent related to this work.</p></sec><sec id="s0060"><title>Author Contributions</title><p>W.A.W., J.K., N.M., C.T., J.S.P, T.C.S, J.S.S, and N.E.S. designed the research, performed research, and analyzed data. A.C.S. contributed to the statistical analysis. W.A.W. and N.E.S. wrote the paper. All authors contributed to the critical review and editing of the manuscript.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Acosta</surname><given-names>J.C.</given-names></name><name><surname>O'loghlen</surname><given-names>A.</given-names></name><name><surname>Banito</surname><given-names>A.</given-names></name><name><surname>Guijarro</surname><given-names>M.V.</given-names></name><name><surname>Augert</surname><given-names>A.</given-names></name><name><surname>Raguz</surname><given-names>S.</given-names></name><name><surname>Fumagalli</surname><given-names>M.</given-names></name><name><surname>Da Costa</surname><given-names>M.</given-names></name><name><surname>Brown</surname><given-names>C.</given-names></name><name><surname>Popov</surname><given-names>N.</given-names></name><name><surname>Takatsu</surname><given-names>Y.</given-names></name><name><surname>Melamed</surname><given-names>J.</given-names></name><name><surname>D'adda di Fagagna</surname><given-names>F.</given-names></name><name><surname>Bernard</surname><given-names>D.</given-names></name><name><surname>Hernando</surname><given-names>E.</given-names></name><name><surname>Gil</surname><given-names>J.</given-names></name></person-group><article-title>Chemokine signaling via the CXCR2 receptor reinforces senescence</article-title><source>Cell</source><volume>133</volume><year>2008</year><fpage>1006</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">18555777</pub-id></element-citation></ref><ref id="bb0010"><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Akbar</surname><given-names>A.N.</given-names></name><name><surname>Henson</surname><given-names>S.M.</given-names></name></person-group><article-title>Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?</article-title><source>Nat. Rev. Immunol.</source><volume>11</volume><year>2011</year><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">21436838</pub-id></element-citation></ref><ref id="bb0015"><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>M.</given-names></name><name><surname>Asai</surname><given-names>O.</given-names></name><name><surname>Kuraishi</surname><given-names>Y.</given-names></name><name><surname>Urashima</surname><given-names>M.</given-names></name><name><surname>Hoshi</surname><given-names>Y.</given-names></name><name><surname>Sakamaki</surname><given-names>H.</given-names></name><name><surname>Yabe</surname><given-names>H.</given-names></name><name><surname>Furukawa</surname><given-names>T.</given-names></name><name><surname>Yamada</surname><given-names>O.</given-names></name><name><surname>Mizoguchi</surname><given-names>H.</given-names></name><name><surname>Yamada</surname><given-names>H.</given-names></name></person-group><article-title>Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation</article-title><source>Bone Marrow Transplant.</source><volume>25</volume><year>2000</year><fpage>441</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">10723589</pub-id></element-citation></ref><ref id="bb0020"><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>D.J.</given-names></name><name><surname>Childs</surname><given-names>B.G.</given-names></name><name><surname>Durik</surname><given-names>M.</given-names></name><name><surname>Wijers</surname><given-names>M.E.</given-names></name><name><surname>Sieben</surname><given-names>C.J.</given-names></name><name><surname>Zhong</surname><given-names>J.</given-names></name><name><surname>Saltness</surname><given-names>R.A.</given-names></name><name><surname>Jeganathan</surname><given-names>K.B.</given-names></name><name><surname>Verzosa</surname><given-names>G.C.</given-names></name><name><surname>Pezeshki</surname><given-names>A.</given-names></name><name><surname>Khazaie</surname><given-names>K.</given-names></name><name><surname>Miller</surname><given-names>J.D.</given-names></name><name><surname>Van Deursen</surname><given-names>J.M.</given-names></name></person-group><article-title>Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan</article-title><source>Nature</source><volume>530</volume><year>2016</year><fpage>184</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">26840489</pub-id></element-citation></ref><ref id="bb0025"><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>S.</given-names></name><name><surname>Groh</surname><given-names>V.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Steinle</surname><given-names>A.</given-names></name><name><surname>Phillips</surname><given-names>J.H.</given-names></name><name><surname>Lanier</surname><given-names>L.L.</given-names></name><name><surname>Spies</surname><given-names>T.</given-names></name></person-group><article-title>Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA</article-title><source>Science</source><volume>285</volume><year>1999</year><fpage>727</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">10426993</pub-id></element-citation></ref><ref id="bb0030"><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>R.</given-names></name><name><surname>Van Heijzen</surname><given-names>K.</given-names></name><name><surname>Palmer</surname><given-names>A.</given-names></name><name><surname>Komiya</surname><given-names>A.</given-names></name><name><surname>Slovak</surname><given-names>M.L.</given-names></name><name><surname>Chang</surname><given-names>K.L.</given-names></name><name><surname>Fung</surname><given-names>H.</given-names></name><name><surname>Krishnan</surname><given-names>A.</given-names></name><name><surname>Molina</surname><given-names>A.</given-names></name><name><surname>Nademanee</surname><given-names>A.</given-names></name><name><surname>O'donnell</surname><given-names>M.</given-names></name><name><surname>Popplewell</surname><given-names>L.</given-names></name><name><surname>Rodriguez</surname><given-names>R.</given-names></name><name><surname>Forman</surname><given-names>S.J.</given-names></name><name><surname>Bhatia</surname><given-names>S.</given-names></name></person-group><article-title>Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma</article-title><source>J. Clin. Oncol.</source><volume>23</volume><year>2005</year><fpage>6699</fpage><lpage>6711</lpage><pub-id pub-id-type="pmid">16170178</pub-id></element-citation></ref><ref id="bb0035"><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Bull</surname><given-names>C.</given-names></name><name><surname>Sobanov</surname><given-names>Y.</given-names></name><name><surname>Rohrdanz</surname><given-names>B.</given-names></name><name><surname>O'brien</surname><given-names>J.</given-names></name><name><surname>Lehrach</surname><given-names>H.</given-names></name><name><surname>Hofer</surname><given-names>E.</given-names></name></person-group><article-title>The centromeric part of the human NK gene complex: linkage of LOX-1 and LY49L with the CD94/NKG2 region</article-title><source>Genes Immun.</source><volume>1</volume><year>2000</year><fpage>280</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">11196705</pub-id></element-citation></ref><ref id="bb0040"><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Campisi</surname><given-names>J.</given-names></name></person-group><article-title>Aging, cellular senescence, and cancer</article-title><source>Annu. Rev. Physiol.</source><volume>75</volume><year>2013</year><fpage>685</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">23140366</pub-id></element-citation></ref><ref id="bb0045"><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Cancer Genome Atlas Research, N.</surname></name></person-group><article-title>Comprehensive genomic characterization of squamous cell lung cancers</article-title><source>Nature</source><volume>489</volume><year>2012</year><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">22960745</pub-id></element-citation></ref><ref id="bb0050"><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>N.L.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>A.H.</given-names></name><name><surname>Nguyen</surname><given-names>C.</given-names></name><name><surname>Wersto</surname><given-names>R.</given-names></name><name><surname>Weng</surname><given-names>N.P.</given-names></name></person-group><article-title>MicroRNA-125b modulates inflammatory chemokine CCL4 expression in immune cells and its reduction causes CCL4 increase with age</article-title><source>Aging Cell</source><volume>14</volume><year>2015</year><fpage>200</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">25620312</pub-id></element-citation></ref><ref id="bb0055"><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>R.E.</given-names></name><name><surname>Brammer</surname><given-names>C.G.</given-names></name></person-group><article-title>Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system</article-title><source>Bone Marrow Transplant.</source><volume>22</volume><year>1998</year><fpage>859</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">9827813</pub-id></element-citation></ref><ref id="bb0060"><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>A.</given-names></name><name><surname>Grolleau-Julius</surname><given-names>A.</given-names></name><name><surname>Yung</surname><given-names>R.</given-names></name></person-group><article-title>Leukocyte function in the aging immune system</article-title><source>J. Leukoc. Biol.</source><volume>87</volume><year>2010</year><fpage>1001</fpage><lpage>1009</lpage><pub-id pub-id-type="pmid">20200405</pub-id></element-citation></ref><ref id="bb0065"><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Dheda</surname><given-names>K.</given-names></name><name><surname>Huggett</surname><given-names>J.F.</given-names></name><name><surname>Bustin</surname><given-names>S.A.</given-names></name><name><surname>Johnson</surname><given-names>M.A.</given-names></name><name><surname>Rook</surname><given-names>G.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name></person-group><article-title>Validation of housekeeping genes for normalizing RNA expression in real-time PCR</article-title><source>Biotechniques</source><volume>37</volume><year>2004</year><fpage>112</fpage><lpage>114</lpage><comment>(116, 118&#x02013;9)</comment><pub-id pub-id-type="pmid">15283208</pub-id></element-citation></ref><ref id="bb0070"><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Dorshkind</surname><given-names>K.</given-names></name><name><surname>Montecino-Rodriguez</surname><given-names>E.</given-names></name><name><surname>Signer</surname><given-names>R.A.</given-names></name></person-group><article-title>The ageing immune system: is it ever too old to become young again?</article-title><source>Nat. Rev. Immunol.</source><volume>9</volume><year>2009</year><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">19104499</pub-id></element-citation></ref><ref id="bb0075"><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Effros</surname><given-names>R.B.</given-names></name><name><surname>Boucher</surname><given-names>N.</given-names></name><name><surname>Porter</surname><given-names>V.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Spaulding</surname><given-names>C.</given-names></name><name><surname>Walford</surname><given-names>R.L.</given-names></name><name><surname>Kronenberg</surname><given-names>M.</given-names></name><name><surname>Cohen</surname><given-names>D.</given-names></name><name><surname>Schachter</surname><given-names>F.</given-names></name></person-group><article-title>Decline in CD28&#x000a0;+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence</article-title><source>Exp. Gerontol.</source><volume>29</volume><year>1994</year><fpage>601</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">9435913</pub-id></element-citation></ref><ref id="bb0080"><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Fried</surname><given-names>L.P.</given-names></name><name><surname>Tangen</surname><given-names>C.M.</given-names></name><name><surname>Walston</surname><given-names>J.</given-names></name><name><surname>Newman</surname><given-names>A.B.</given-names></name><name><surname>Hirsch</surname><given-names>C.</given-names></name><name><surname>Gottdiener</surname><given-names>J.</given-names></name><name><surname>Seeman</surname><given-names>T.</given-names></name><name><surname>Tracy</surname><given-names>R.</given-names></name><name><surname>Kop</surname><given-names>W.J.</given-names></name><name><surname>Burke</surname><given-names>G.</given-names></name><name><surname>Mcburnie</surname><given-names>M.A.</given-names></name><collab>Cardiovascular Health Study Collaborative Research, G.</collab></person-group><article-title>Frailty in older adults: evidence for a phenotype</article-title><source>J. Gerontol. A Biol. Sci. Med. Sci.</source><volume>56</volume><year>2001</year><fpage>M146</fpage><lpage>M156</lpage><pub-id pub-id-type="pmid">11253156</pub-id></element-citation></ref><ref id="bb0085"><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Gingell-Littlejohn</surname><given-names>M.</given-names></name><name><surname>Mcguinness</surname><given-names>D.</given-names></name><name><surname>Mcglynn</surname><given-names>L.M.</given-names></name><name><surname>Kingsmore</surname><given-names>D.</given-names></name><name><surname>Stevenson</surname><given-names>K.S.</given-names></name><name><surname>Koppelstaetter</surname><given-names>C.</given-names></name><name><surname>Clancy</surname><given-names>M.J.</given-names></name><name><surname>Shiels</surname><given-names>P.G.</given-names></name></person-group><article-title>Pre-transplant CDKN2A expression in kidney biopsies predicts renal function and is a future component of donor scoring criteria</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e68133</object-id></element-citation></ref><ref id="bb0090"><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Goronzy</surname><given-names>J.J.</given-names></name><name><surname>Weyand</surname><given-names>C.M.</given-names></name></person-group><article-title>T cell development and receptor diversity during aging</article-title><source>Curr. Opin. Immunol.</source><volume>17</volume><year>2005</year><fpage>468</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">16098723</pub-id></element-citation></ref><ref id="bb0095"><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Hake</surname><given-names>C.R.</given-names></name><name><surname>Graubert</surname><given-names>T.A.</given-names></name><name><surname>Fenske</surname><given-names>T.S.</given-names></name></person-group><article-title>Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?</article-title><source>Bone Marrow Transplant.</source><volume>39</volume><year>2007</year><fpage>59</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">17143301</pub-id></element-citation></ref><ref id="bb0100"><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Hammond</surname><given-names>S.M.</given-names></name><name><surname>Sharpless</surname><given-names>N.E.</given-names></name></person-group><article-title>HMGA2, microRNAs, and stem cell aging</article-title><source>Cell</source><volume>135</volume><year>2008</year><fpage>1013</fpage><lpage>1016</lpage><pub-id pub-id-type="pmid">19070572</pub-id></element-citation></ref><ref id="bb0105"><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>D.E.</given-names></name></person-group><article-title>Proliferative capacity of erythropoietic stem cell lines and aging: an overview</article-title><source>Mech. Ageing Dev.</source><volume>9</volume><year>1979</year><fpage>409</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">37376</pub-id></element-citation></ref><ref id="bb0110"><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>D.E.</given-names></name><name><surname>Astle</surname><given-names>C.M.</given-names></name></person-group><article-title>Loss of stem cell repopulating ability upon transplantation. Effects of donor age, cell number, and transplantation procedure</article-title><source>J. Exp. Med.</source><volume>156</volume><year>1982</year><fpage>1767</fpage><lpage>1779</lpage><pub-id pub-id-type="pmid">6129277</pub-id></element-citation></ref><ref id="bb0115"><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Humbert</surname><given-names>N.</given-names></name><name><surname>Navaratnam</surname><given-names>N.</given-names></name><name><surname>Augert</surname><given-names>A.</given-names></name><name><surname>Da Costa</surname><given-names>M.</given-names></name><name><surname>Martien</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Martinez</surname><given-names>D.</given-names></name><name><surname>Abbadie</surname><given-names>C.</given-names></name><name><surname>Carling</surname><given-names>D.</given-names></name><name><surname>De Launoit</surname><given-names>Y.</given-names></name><name><surname>Gil</surname><given-names>J.</given-names></name><name><surname>Bernard</surname><given-names>D.</given-names></name></person-group><article-title>Regulation of ploidy and senescence by the AMPK-related kinase NUAK1</article-title><source>EMBO J.</source><volume>29</volume><year>2010</year><fpage>376</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">19927127</pub-id></element-citation></ref><ref id="bb0120"><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Janzen</surname><given-names>V.</given-names></name><name><surname>Forkert</surname><given-names>R.</given-names></name><name><surname>Fleming</surname><given-names>H.E.</given-names></name><name><surname>Saito</surname><given-names>Y.</given-names></name><name><surname>Waring</surname><given-names>M.T.</given-names></name><name><surname>Dombkowski</surname><given-names>D.M.</given-names></name><name><surname>Cheng</surname><given-names>T.</given-names></name><name><surname>Depinho</surname><given-names>R.A.</given-names></name><name><surname>Sharpless</surname><given-names>N.E.</given-names></name><name><surname>Scadden</surname><given-names>D.T.</given-names></name></person-group><article-title>Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16<sup>INK4a</sup></article-title><source>Nature</source><volume>443</volume><year>2006</year><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">16957735</pub-id></element-citation></ref><ref id="bb0125"><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>Jaruga</surname><given-names>E.</given-names></name><name><surname>Skierski</surname><given-names>J.</given-names></name><name><surname>Radziszewska</surname><given-names>E.</given-names></name><name><surname>Sikora</surname><given-names>E.</given-names></name></person-group><article-title>Proliferation and apoptosis of human T cells during replicative senescence&#x02013;a critical approach</article-title><source>Acta Biochim. Pol.</source><volume>47</volume><year>2000</year><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">11051194</pub-id></element-citation></ref><ref id="bb0130"><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Jeck</surname><given-names>W.R.</given-names></name><name><surname>Siebold</surname><given-names>A.P.</given-names></name><name><surname>Sharpless</surname><given-names>N.E.</given-names></name></person-group><article-title>Review: a meta-analysis of GWAS and age-associated diseases</article-title><source>Aging Cell</source><volume>11</volume><year>2012</year><fpage>727</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">22888763</pub-id></element-citation></ref><ref id="bb0135"><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>Koppelstaetter</surname><given-names>C.</given-names></name><name><surname>Schratzberger</surname><given-names>G.</given-names></name><name><surname>Perco</surname><given-names>P.</given-names></name><name><surname>Hofer</surname><given-names>J.</given-names></name><name><surname>Mark</surname><given-names>W.</given-names></name><name><surname>Ollinger</surname><given-names>R.</given-names></name><name><surname>Oberbauer</surname><given-names>R.</given-names></name><name><surname>Schwarz</surname><given-names>C.</given-names></name><name><surname>Mitterbauer</surname><given-names>C.</given-names></name><name><surname>Kainz</surname><given-names>A.</given-names></name><name><surname>Karkoszka</surname><given-names>H.</given-names></name><name><surname>Wiecek</surname><given-names>A.</given-names></name><name><surname>Mayer</surname><given-names>B.</given-names></name><name><surname>Mayer</surname><given-names>G.</given-names></name></person-group><article-title>Markers of cellular senescence in zero hour biopsies predict outcome in renal transplantation</article-title><source>Aging Cell</source><volume>7</volume><year>2008</year><fpage>491</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">18462273</pub-id></element-citation></ref><ref id="bb0140"><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Krishnamurthy</surname><given-names>J.</given-names></name><name><surname>Torrice</surname><given-names>C.</given-names></name><name><surname>Ramsey</surname><given-names>M.R.</given-names></name><name><surname>Kovalev</surname><given-names>G.I.</given-names></name><name><surname>Al-Regaiey</surname><given-names>K.</given-names></name><name><surname>Su</surname><given-names>L.</given-names></name><name><surname>Sharpless</surname><given-names>N.E.</given-names></name></person-group><article-title>Ink4a/Arf expression is a biomarker of aging</article-title><source>J. Clin. Invest.</source><volume>114</volume><year>2004</year><fpage>1299</fpage><lpage>1307</lpage><pub-id pub-id-type="pmid">15520862</pub-id></element-citation></ref><ref id="bb0145"><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Lansdorp</surname><given-names>P.M.</given-names></name></person-group><article-title>Immortal strands? Give me a break</article-title><source>Cell</source><volume>129</volume><year>2007</year><fpage>1244</fpage><lpage>1247</lpage><pub-id pub-id-type="pmid">17604711</pub-id></element-citation></ref><ref id="bb0150"><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Kook</surname><given-names>H.</given-names></name><name><surname>Chung</surname><given-names>I.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Park</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>C.</given-names></name><name><surname>Nah</surname><given-names>J.</given-names></name><name><surname>Hwang</surname><given-names>T.</given-names></name></person-group><article-title>Telomere length changes in patients undergoing hematopoietic stem cell transplantation</article-title><source>Bone Marrow Transplant.</source><volume>24</volume><year>1999</year><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">10467331</pub-id></element-citation></ref><ref id="bb0155"><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Lemster</surname><given-names>B.H.</given-names></name><name><surname>Michel</surname><given-names>J.J.</given-names></name><name><surname>Montag</surname><given-names>D.T.</given-names></name><name><surname>Paat</surname><given-names>J.J.</given-names></name><name><surname>Studenski</surname><given-names>S.A.</given-names></name><name><surname>Newman</surname><given-names>A.B.</given-names></name><name><surname>Vallejo</surname><given-names>A.N.</given-names></name></person-group><article-title>Induction of CD56 and TCR-independent activation of T cells with aging</article-title><source>J. Immunol.</source><volume>180</volume><year>2008</year><fpage>1979</fpage><lpage>1990</lpage><pub-id pub-id-type="pmid">18209097</pub-id></element-citation></ref><ref id="bb0160"><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>N.L.</given-names></name><name><surname>Mullaney</surname><given-names>M.</given-names></name><name><surname>Mangan</surname><given-names>K.F.</given-names></name><name><surname>Klumpp</surname><given-names>T.</given-names></name><name><surname>Rogatko</surname><given-names>A.</given-names></name><name><surname>Broccoli</surname><given-names>D.</given-names></name></person-group><article-title>Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients</article-title><source>Bone Marrow Transplant.</source><volume>33</volume><year>2004</year><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">14704659</pub-id></element-citation></ref><ref id="bb0165"><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Dewey</surname><given-names>C.N.</given-names></name></person-group><article-title>RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome</article-title><source>BMC Bioinf.</source><volume>12</volume><year>2011</year><fpage>323</fpage></element-citation></ref><ref id="bb0170"><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name><surname>Linton</surname><given-names>P.J.</given-names></name><name><surname>Dorshkind</surname><given-names>K.</given-names></name></person-group><article-title>Age-related changes in lymphocyte development and function</article-title><source>Nat. Immunol.</source><volume>5</volume><year>2004</year><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">14749784</pub-id></element-citation></ref><ref id="bb0175"><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Sanoff</surname><given-names>H.K.</given-names></name><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>Burd</surname><given-names>C.E.</given-names></name><name><surname>Torrice</surname><given-names>C.</given-names></name><name><surname>Ibrahim</surname><given-names>J.G.</given-names></name><name><surname>Thomas</surname><given-names>N.E.</given-names></name><name><surname>Sharpless</surname><given-names>N.E.</given-names></name></person-group><article-title>Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging</article-title><source>Aging Cell</source><volume>8</volume><year>2009</year><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">19485966</pub-id></element-citation></ref><ref id="bb0180"><element-citation publication-type="journal" id="rf0180"><person-group person-group-type="author"><name><surname>Love</surname><given-names>M.I.</given-names></name><name><surname>Huber</surname><given-names>W.</given-names></name><name><surname>Anders</surname><given-names>S.</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol.</source><volume>15</volume><year>2014</year><fpage>550</fpage><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bb0185"><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name><surname>Mane</surname><given-names>V.P.</given-names></name><name><surname>Heuer</surname><given-names>M.A.</given-names></name><name><surname>Hillyer</surname><given-names>P.</given-names></name><name><surname>Navarro</surname><given-names>M.B.</given-names></name><name><surname>Rabin</surname><given-names>R.L.</given-names></name></person-group><article-title>Systematic method for determining an ideal housekeeping gene for real-time PCR analysis</article-title><source>J. Biomol. Tech.</source><volume>19</volume><year>2008</year><fpage>342</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">19183798</pub-id></element-citation></ref><ref id="bb0190"><element-citation publication-type="journal" id="rf0190"><person-group person-group-type="author"><name><surname>Mcglynn</surname><given-names>L.M.</given-names></name><name><surname>Stevenson</surname><given-names>K.</given-names></name><name><surname>Lamb</surname><given-names>K.</given-names></name><name><surname>Zino</surname><given-names>S.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Prina</surname><given-names>A.</given-names></name><name><surname>Kingsmore</surname><given-names>D.</given-names></name><name><surname>Shiels</surname><given-names>P.G.</given-names></name></person-group><article-title>Cellular senescence in pretransplant renal biopsies predicts postoperative organ function</article-title><source>Aging Cell</source><volume>8</volume><year>2009</year><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">19067655</pub-id></element-citation></ref><ref id="bb0195"><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name><surname>Min</surname><given-names>H.</given-names></name><name><surname>Montecino-Rodriguez</surname><given-names>E.</given-names></name><name><surname>Dorshkind</surname><given-names>K.</given-names></name></person-group><article-title>Effects of aging on early B- and T-cell development</article-title><source>Immunol. Rev.</source><volume>205</volume><year>2005</year><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">15882341</pub-id></element-citation></ref><ref id="bb0200"><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name><surname>Montecino-Rodriguez</surname><given-names>E.</given-names></name><name><surname>Berent-Maoz</surname><given-names>B.</given-names></name><name><surname>Dorshkind</surname><given-names>K.</given-names></name></person-group><article-title>Causes, consequences, and reversal of immune system aging</article-title><source>J. Clin. Invest.</source><volume>123</volume><year>2013</year><fpage>958</fpage><lpage>965</lpage><pub-id pub-id-type="pmid">23454758</pub-id></element-citation></ref><ref id="bb0205"><element-citation publication-type="journal" id="rf0205"><person-group person-group-type="author"><name><surname>Narita</surname><given-names>M.</given-names></name><name><surname>Narita</surname><given-names>M.</given-names></name><name><surname>Krizhanovsky</surname><given-names>V.</given-names></name><name><surname>Nunez</surname><given-names>S.</given-names></name><name><surname>Chicas</surname><given-names>A.</given-names></name><name><surname>Hearn</surname><given-names>S.A.</given-names></name><name><surname>Myers</surname><given-names>M.P.</given-names></name><name><surname>Lowe</surname><given-names>S.W.</given-names></name></person-group><article-title>A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation</article-title><source>Cell</source><volume>126</volume><year>2006</year><fpage>503</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">16901784</pub-id></element-citation></ref><ref id="bb0210"><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>J.A.</given-names></name><name><surname>Krishnamurthy</surname><given-names>J.</given-names></name><name><surname>Menezes</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Hudgens</surname><given-names>M.G.</given-names></name><name><surname>Sharpless</surname><given-names>N.E.</given-names></name><name><surname>Eron</surname><given-names>J.J.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Expression of p16(INK4a) as a biomarker of T-cell aging in HIV-infected patients prior to and during antiretroviral therapy</article-title><source>Aging Cell</source><volume>11</volume><year>2012</year><fpage>916</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">22738669</pub-id></element-citation></ref><ref id="bb0215"><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name><surname>Perez-Simon</surname><given-names>J.A.</given-names></name><name><surname>Martin</surname><given-names>A.</given-names></name><name><surname>Caballero</surname><given-names>D.</given-names></name><name><surname>Corral</surname><given-names>M.</given-names></name><name><surname>Nieto</surname><given-names>M.J.</given-names></name><name><surname>Gonzalez</surname><given-names>M.</given-names></name><name><surname>Vazquez</surname><given-names>L.</given-names></name><name><surname>Lopez-Berges</surname><given-names>C.</given-names></name><name><surname>Canizo</surname><given-names>M.C.</given-names></name><name><surname>Mateos</surname><given-names>M.V.</given-names></name><name><surname>Orfao</surname><given-names>A.</given-names></name><name><surname>San Miguel</surname><given-names>J.F.</given-names></name></person-group><article-title>Clinical significance of CD34&#x000a0;+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation</article-title><source>Bone Marrow Transplant.</source><volume>24</volume><year>1999</year><fpage>1279</fpage><lpage>1283</lpage><pub-id pub-id-type="pmid">10627635</pub-id></element-citation></ref><ref id="bb0220"><element-citation publication-type="journal" id="rf0220"><person-group person-group-type="author"><name><surname>Perillo</surname><given-names>N.L.</given-names></name><name><surname>Naeim</surname><given-names>F.</given-names></name><name><surname>Walford</surname><given-names>R.L.</given-names></name><name><surname>Effros</surname><given-names>R.B.</given-names></name></person-group><article-title>The in vitro senescence of human T lymphocytes: failure to divide is not associated with a loss of cytolytic activity or memory T cell phenotype</article-title><source>Mech. Ageing Dev.</source><volume>67</volume><year>1993</year><fpage>173</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">8469029</pub-id></element-citation></ref><ref id="bb0225"><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name><surname>Pipes</surname><given-names>B.L.</given-names></name><name><surname>Tsang</surname><given-names>T.</given-names></name><name><surname>Peng</surname><given-names>S.X.</given-names></name><name><surname>Fiederlein</surname><given-names>R.</given-names></name><name><surname>Graham</surname><given-names>M.</given-names></name><name><surname>Harris</surname><given-names>D.T.</given-names></name></person-group><article-title>Telomere length changes after umbilical cord blood transplant</article-title><source>Transfusion</source><volume>46</volume><year>2006</year><fpage>1038</fpage><lpage>1043</lpage><pub-id pub-id-type="pmid">16734822</pub-id></element-citation></ref><ref id="bb0230"><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name><surname>Robin</surname><given-names>J.D.</given-names></name><name><surname>Ludlow</surname><given-names>A.T.</given-names></name><name><surname>Batten</surname><given-names>K.</given-names></name><name><surname>Magdinier</surname><given-names>F.</given-names></name><name><surname>Stadler</surname><given-names>G.</given-names></name><name><surname>Wagner</surname><given-names>K.R.</given-names></name><name><surname>Shay</surname><given-names>J.W.</given-names></name><name><surname>Wright</surname><given-names>W.E.</given-names></name></person-group><article-title>Telomere position effect: regulation of gene expression with progressive telomere shortening over long distances</article-title><source>Genes Dev.</source><volume>28</volume><year>2014</year><fpage>2464</fpage><lpage>2476</lpage><pub-id pub-id-type="pmid">25403178</pub-id></element-citation></ref><ref id="bb0235"><element-citation publication-type="journal" id="rf0235"><person-group person-group-type="author"><name><surname>Rodier</surname><given-names>F.</given-names></name><name><surname>Campisi</surname><given-names>J.</given-names></name></person-group><article-title>Four faces of cellular senescence</article-title><source>J. Cell Biol.</source><volume>192</volume><year>2011</year><fpage>547</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">21321098</pub-id></element-citation></ref><ref id="bb0240"><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name><surname>Rosko</surname><given-names>A.</given-names></name><name><surname>Hofmeister</surname><given-names>C.</given-names></name><name><surname>Benson</surname><given-names>D.</given-names></name><name><surname>Efebera</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Gillahan</surname><given-names>J.</given-names></name><name><surname>Byrd</surname><given-names>J.C.</given-names></name><name><surname>Burd</surname><given-names>C.E.</given-names></name></person-group><article-title>Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma</article-title><source>Bone Marrow Transplant.</source><volume>50</volume><year>2015</year><fpage>1379</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">26121107</pub-id></element-citation></ref><ref id="bb0245"><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name><surname>Sanoff</surname><given-names>H.K.</given-names></name><name><surname>Deal</surname><given-names>A.M.</given-names></name><name><surname>Krishnamurthy</surname><given-names>J.</given-names></name><name><surname>Torrice</surname><given-names>C.</given-names></name><name><surname>Dillon</surname><given-names>P.</given-names></name><name><surname>Sorrentino</surname><given-names>J.</given-names></name><name><surname>Ibrahim</surname><given-names>J.G.</given-names></name><name><surname>Jolly</surname><given-names>T.A.</given-names></name><name><surname>Williams</surname><given-names>G.</given-names></name><name><surname>Carey</surname><given-names>L.A.</given-names></name><name><surname>Drobish</surname><given-names>A.</given-names></name><name><surname>Gordon</surname><given-names>B.B.</given-names></name><name><surname>Alston</surname><given-names>S.</given-names></name><name><surname>Hurria</surname><given-names>A.</given-names></name><name><surname>Kleinhans</surname><given-names>K.</given-names></name><name><surname>Rudolph</surname><given-names>K.L.</given-names></name><name><surname>Sharpless</surname><given-names>N.E.</given-names></name><name><surname>Muss</surname><given-names>H.B.</given-names></name></person-group><article-title>Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer</article-title><source>J. Natl. Cancer Inst.</source><volume>106</volume><year>2014</year><comment>(dju057)</comment></element-citation></ref><ref id="bb0250"><element-citation publication-type="journal" id="rf0250"><person-group person-group-type="author"><name><surname>Sciume</surname><given-names>G.</given-names></name><name><surname>de Angelis</surname><given-names>G.</given-names></name><name><surname>Benigni</surname><given-names>G.</given-names></name><name><surname>Ponzetta</surname><given-names>A.</given-names></name><name><surname>Morrone</surname><given-names>S.</given-names></name><name><surname>Santoni</surname><given-names>A.</given-names></name><name><surname>Bernardini</surname><given-names>G.</given-names></name></person-group><article-title>CX3CR1 expression defines 2 KLRG1&#x000a0;+ mouse NK-cell subsets with distinct functional properties and positioning in the bone marrow</article-title><source>Blood</source><volume>117</volume><year>2011</year><fpage>4467</fpage><lpage>4475</lpage><pub-id pub-id-type="pmid">21364193</pub-id></element-citation></ref><ref id="bb0255"><element-citation publication-type="journal" id="rf0255"><person-group person-group-type="author"><name><surname>Sharpless</surname><given-names>N.E.</given-names></name><name><surname>Depinho</surname><given-names>R.A.</given-names></name></person-group><article-title>How stem cells age and why this makes us grow old</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>8</volume><year>2007</year><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">17717515</pub-id></element-citation></ref><ref id="bb0260"><element-citation publication-type="journal" id="rf0260"><person-group person-group-type="author"><name><surname>Sharpless</surname><given-names>N.E.</given-names></name><name><surname>Sherr</surname><given-names>C.J.</given-names></name></person-group><article-title>Forging a signature of in vivo senescence</article-title><source>Nat. Rev. Cancer</source><volume>15</volume><year>2015</year><fpage>397</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">26105537</pub-id></element-citation></ref><ref id="bb0265"><element-citation publication-type="journal" id="rf0265"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.</given-names></name><name><surname>Desantis</surname><given-names>C.</given-names></name><name><surname>Virgo</surname><given-names>K.</given-names></name><name><surname>Stein</surname><given-names>K.</given-names></name><name><surname>Mariotto</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>T.</given-names></name><name><surname>Cooper</surname><given-names>D.</given-names></name><name><surname>Gansler</surname><given-names>T.</given-names></name><name><surname>Lerro</surname><given-names>C.</given-names></name><name><surname>Fedewa</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>C.</given-names></name><name><surname>Leach</surname><given-names>C.</given-names></name><name><surname>Cannady</surname><given-names>R.S.</given-names></name><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>Scoppa</surname><given-names>S.</given-names></name><name><surname>Hachey</surname><given-names>M.</given-names></name><name><surname>Kirch</surname><given-names>R.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name><name><surname>Ward</surname><given-names>E.</given-names></name></person-group><article-title>Cancer treatment and survivorship statistics, 2012</article-title><source>CA Cancer J. Clin.</source><volume>62</volume><year>2012</year><fpage>220</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">22700443</pub-id></element-citation></ref><ref id="bb0270"><element-citation publication-type="journal" id="rf0270"><person-group person-group-type="author"><name><surname>Soriani</surname><given-names>A.</given-names></name><name><surname>Iannitto</surname><given-names>M.L.</given-names></name><name><surname>Ricci</surname><given-names>B.</given-names></name><name><surname>Fionda</surname><given-names>C.</given-names></name><name><surname>Malgarini</surname><given-names>G.</given-names></name><name><surname>Morrone</surname><given-names>S.</given-names></name><name><surname>Peruzzi</surname><given-names>G.</given-names></name><name><surname>Ricciardi</surname><given-names>M.R.</given-names></name><name><surname>Petrucci</surname><given-names>M.T.</given-names></name><name><surname>Cippitelli</surname><given-names>M.</given-names></name><name><surname>Santoni</surname><given-names>A.</given-names></name></person-group><article-title>Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1</article-title><source>J. Immunol.</source><volume>193</volume><year>2014</year><fpage>950</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">24913980</pub-id></element-citation></ref><ref id="bb0275"><element-citation publication-type="journal" id="rf0275"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A.</given-names></name><name><surname>Tamayo</surname><given-names>P.</given-names></name><name><surname>Mootha</surname><given-names>V.K.</given-names></name><name><surname>Mukherjee</surname><given-names>S.</given-names></name><name><surname>Ebert</surname><given-names>B.L.</given-names></name><name><surname>Gillette</surname><given-names>M.A.</given-names></name><name><surname>Paulovich</surname><given-names>A.</given-names></name><name><surname>Pomeroy</surname><given-names>S.L.</given-names></name><name><surname>Golub</surname><given-names>T.R.</given-names></name><name><surname>Lander</surname><given-names>E.S.</given-names></name><name><surname>Mesirov</surname><given-names>J.P.</given-names></name></person-group><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>102</volume><year>2005</year><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bb0280"><element-citation publication-type="journal" id="rf0280"><person-group person-group-type="author"><name><surname>Targonski</surname><given-names>P.V.</given-names></name><name><surname>Jacobson</surname><given-names>R.M.</given-names></name><name><surname>Poland</surname><given-names>G.A.</given-names></name></person-group><article-title>Immunosenescence: role and measurement in influenza vaccine response among the elderly</article-title><source>Vaccine</source><volume>25</volume><year>2007</year><fpage>3066</fpage><lpage>3069</lpage><pub-id pub-id-type="pmid">17275144</pub-id></element-citation></ref><ref id="bb0285"><element-citation publication-type="journal" id="rf0285"><person-group person-group-type="author"><name><surname>Textor</surname><given-names>S.</given-names></name><name><surname>Fiegler</surname><given-names>N.</given-names></name><name><surname>Arnold</surname><given-names>A.</given-names></name><name><surname>Porgador</surname><given-names>A.</given-names></name><name><surname>Hofmann</surname><given-names>T.G.</given-names></name><name><surname>Cerwenka</surname><given-names>A.</given-names></name></person-group><article-title>Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2</article-title><source>Cancer Res.</source><volume>71</volume><year>2011</year><fpage>5998</fpage><lpage>6009</lpage><pub-id pub-id-type="pmid">21764762</pub-id></element-citation></ref><ref id="bb0290"><element-citation publication-type="journal" id="rf0290"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Singh</surname><given-names>D.</given-names></name><name><surname>Zeng</surname><given-names>Z.</given-names></name><name><surname>Coleman</surname><given-names>S.J.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Savich</surname><given-names>G.L.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Mieczkowski</surname><given-names>P.</given-names></name><name><surname>Grimm</surname><given-names>S.A.</given-names></name><name><surname>Perou</surname><given-names>C.M.</given-names></name><name><surname>Macleod</surname><given-names>J.N.</given-names></name><name><surname>Chiang</surname><given-names>D.Y.</given-names></name><name><surname>Prins</surname><given-names>J.F.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>MapSplice: accurate mapping of RNA-seq reads for splice junction discovery</article-title><source>Nucleic Acids Res.</source><volume>38</volume><year>2010</year><object-id pub-id-type="publisher-id">e178</object-id></element-citation></ref><ref id="bb0295"><element-citation publication-type="journal" id="rf0295"><person-group person-group-type="author"><name><surname>Wildes</surname><given-names>T.M.</given-names></name><name><surname>Rosko</surname><given-names>A.</given-names></name><name><surname>Tuchman</surname><given-names>S.A.</given-names></name></person-group><article-title>Multiple myeloma in the older adult: better prospects, more challenges</article-title><source>J. Clin. Oncol.</source><volume>32</volume><year>2014</year><fpage>2531</fpage><lpage>2540</lpage><pub-id pub-id-type="pmid">25071143</pub-id></element-citation></ref><ref id="bb0300"><element-citation publication-type="journal" id="rf0300"><person-group person-group-type="author"><name><surname>Woolthuis</surname><given-names>C.M.</given-names></name><name><surname>Mariani</surname><given-names>N.</given-names></name><name><surname>Verkaik-Schakel</surname><given-names>R.N.</given-names></name><name><surname>Brouwers-Vos</surname><given-names>A.Z.</given-names></name><name><surname>Schuringa</surname><given-names>J.J.</given-names></name><name><surname>Vellenga</surname><given-names>E.</given-names></name><name><surname>De Wolf</surname><given-names>J.T.</given-names></name><name><surname>Huls</surname><given-names>G.</given-names></name></person-group><article-title>Aging impairs long-term hematopoietic regeneration after autologous stem cell transplantation</article-title><source>Biol. Blood Marrow Transplant.</source><volume>20</volume><year>2014</year><fpage>865</fpage><lpage>871</lpage><pub-id pub-id-type="pmid">24607555</pub-id></element-citation></ref><ref id="bb0305"><element-citation publication-type="journal" id="rf0305"><person-group person-group-type="author"><name><surname>Zindy</surname><given-names>F.</given-names></name><name><surname>Quelle</surname><given-names>D.E.</given-names></name><name><surname>Roussel</surname><given-names>M.F.</given-names></name><name><surname>Sherr</surname><given-names>C.J.</given-names></name></person-group><article-title>Expression of the p16<sup>INK4a</sup> tumor suppressor versus other INK4 family members during mouse development and aging</article-title><source>Oncogene</source><volume>15</volume><year>1997</year><fpage>203</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">9244355</pub-id></element-citation></ref></ref-list><ack id="ac0005"><title>Acknowledgements</title><p>The authors wish to acknowledge the contributions of Hanna Sanoff, whose Breast Cancer Samples (<xref rid="bb0245" ref-type="bibr">Sanoff et al., 2014</xref>) were used in the current analysis; Wenjin Liu, who contributed to the analysis of the RNA sequencing data; and Lei Lei, who contributed to the clinical data acquisition and analysis.</p></ack></back><floats-group><fig id="f0005"><label>Fig. 1</label><caption><p>A hierarchical clustering of representative transcripts whose expression significantly changes with cancer therapy (3 pair of auto-HSCT samples or 5 pair of chemotherapy-treated samples) in peripheral blood T-cells (CD3&#x000a0;+). Pre-treatment samples are on the left (grey bar above the heatmap) and post-treatment samples are on the right (blue bar). Genes of interest are ordered along the y-axis as described in the <xref rid="s0035" ref-type="sec">Results</xref> section, with color-coding indicated to the left of the heatmap (purple&#x000a0;=&#x000a0;senescence associated; light blue&#x000a0;=&#x000a0;telomere shortening; brown&#x000a0;=&#x000a0;effector; yellow&#x000a0;=&#x000a0;NK; orange&#x000a0;=&#x000a0;exhaustion). Sample numbers are shown below the heatmap, with an &#x0201c;A&#x0201d; prior to sample numbers indicating patients undergoing auto-HSCT. Samples without an &#x0201c;A&#x0201d; indicate patients treated with chemotherapy and not transplantation. Samples are ordered along the x-axis.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig><fig id="f0010"><label>Fig. 2</label><caption><p>A hierarchical clustering of all transcripts whose expression significantly changes with cancer therapy (3 pair of auto-HSCT samples or 5 pair of chemotherapy-treated samples) in peripheral blood T-cells (CD3&#x000a0;+). Pre-treatment samples are on the left (grey bar above the heatmap) and post-treatment samples are on the right (blue bar). Sample numbers are shown below the heatmap, with an &#x0201c;A&#x0201d; prior to sample numbers indicating patients undergoing auto-HSCT. Samples without an &#x0201c;A&#x0201d; indicate patients treated with chemotherapy and not transplantation. Samples are ordered along the x-axis as in <xref rid="f0005" ref-type="fig">Fig. 1</xref>.</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig><fig id="f0015"><label>Fig. 3</label><caption><p>A hierarchical clustering of transcripts from a Gene Set Enrichment Analysis Signature (GSE11057) with increased expression in memory CD4&#x000a0;+ cells compared to na&#x000ef;ve cells. Pre-treatment samples are on the left (grey bar above the heatmap) and post-treatment samples are on the right (blue bar). Sample numbers are shown below the heatmap, with an &#x0201c;A&#x0201d; prior to sample numbers indicating patients undergoing auto-HSCT. Samples without an &#x0201c;A&#x0201d; indicate patients treated with chemotherapy and not transplantation. Samples are ordered along the x-axis as in <xref rid="f0005" ref-type="fig">Fig. 1</xref>.</p></caption><alt-text id="al0015">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig><fig id="f0020"><label>Fig. 4</label><caption><p>A hierarchical clustering of transcripts from a Gene Set Enrichment Analysis Signature (GSE26928) with increased expression in effector memory compared to central memory CD4&#x000a0;+ cells. Pre-treatment samples are on the left (grey bar above the heatmap) and post-treatment samples are on the right (blue bar). Sample numbers are shown below the heatmap, with an &#x0201c;A&#x0201d; prior to sample numbers indicating patients undergoing auto-HSCT. Samples without an &#x0201c;A&#x0201d; indicate patients treated with chemotherapy and not transplantation. Samples are ordered along the x-axis as in <xref rid="f0005" ref-type="fig">Fig. 1</xref>.</p></caption><alt-text id="al0020">Fig. 4</alt-text><graphic xlink:href="gr4"/></fig><fig id="f0025"><label>Fig. 5</label><caption><p>A hierarchical clustering of transcripts from a Gene Set Enrichment Analysis Signature (GSE22045) with increased expression in regulatory T cells compared to conventional T cells. Pre-treatment samples are on the left (grey bar above the heatmap) and post-treatment samples are on the right (blue bar). Samples are ordered along the x-axis as in <xref rid="f0005" ref-type="fig">Fig. 1</xref>.</p></caption><alt-text id="al0025">Fig. 5</alt-text><graphic xlink:href="gr5"/></fig><fig id="f0030"><label>Fig. 6</label><caption><p>A hierarchical clustering of transcripts from a Gene Set Enrichment Analysis Signature (GSE36476) with increased expression of transcripts that are more highly expressed in T cells from old versus young donors. Pre-treatment samples are on the left (grey bar above the heatmap) and post-treatment samples are on the right (blue bar). Samples are ordered along the x-axis as in <xref rid="f0005" ref-type="fig">Fig. 1</xref>.</p></caption><alt-text id="al0030">Fig. 6</alt-text><graphic xlink:href="gr6"/></fig><fig id="f0035"><label>Fig. 7</label><caption><p>A hierarchical clustering of transcripts from a Gene Set Enrichment Analysis Signature (GSE9650) with a mixed pattern of expression of signatures associated with na&#x000ef;ve versus exhausted CD8&#x000a0;+ cells. Pre-treatment samples are on the left (grey bar above the heatmap) and post-treatment samples are on the right (blue bar). Sample numbers are shown below the heatmap, with an &#x0201c;A&#x0201d; prior to sample numbers indicating patients undergoing auto-HSCT. Samples without an &#x0201c;A&#x0201d; indicate patients treated with chemotherapy and not transplantation. Samples are ordered along the x-axis as in <xref rid="f0005" ref-type="fig">Fig. 1</xref>.</p></caption><alt-text id="al0035">Fig. 7</alt-text><graphic xlink:href="gr7"/></fig><table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Summary of clinical samples used in this study.</p></caption><alt-text id="al0040">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>Number of samples</th></tr></thead><tbody><tr><td>Symptom burden observational study<xref rid="tf0005" ref-type="table-fn">a</xref></td><td/></tr><tr><td>&#x000a0;Baseline samples</td><td>28</td></tr><tr><td>&#x000a0;Autologous transplant</td><td>8</td></tr><tr><td>&#x000a0;Allogeneic transplant</td><td>20</td></tr><tr><td>&#x000a0;6-month follow up samples</td><td>16</td></tr><tr><td>&#x000a0;Autologous transplant</td><td>5</td></tr><tr><td>&#x000a0;Allogeneic transplant</td><td>11</td></tr><tr><td>Tissue procurement observational study</td><td/></tr><tr><td>&#x000a0;Baseline samples</td><td>35</td></tr><tr><td>&#x000a0;Autologous transplant</td><td>18</td></tr><tr><td>&#x000a0;Allogeneic transplant</td><td>17</td></tr><tr><td>&#x000a0;6-month follow up samples</td><td>11</td></tr><tr><td>&#x000a0;Autologous transplant</td><td>1</td></tr><tr><td>&#x000a0;Allogeneic transplant</td><td>10</td></tr></tbody></table><table-wrap-foot><fn id="tf0005"><label>a</label><p id="np0005">17 patients participating in the symptom burden study also had specimens stored in the tissue procurement facility and collected in the second cohort. In all, 21 samples were shared between the two cohorts- 17 baseline samples and four 6-month follow-up samples. These samples are not counted in the second cohort summary table above.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0010" position="float"><label>Table 2</label><caption><p>Baseline characteristics of hematopoietic stem cell transplantation (HSCT) patients in this study.</p></caption><alt-text id="al0045">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Autologous HSCT</th><th>Allogeneic HSCT</th><th>Total</th></tr></thead><tbody><tr><td>N</td><td>26</td><td>37</td><td>63</td></tr><tr><td>Age (mean (SD))</td><td>59.0 (8.6)</td><td>54.2 (11.4)</td><td>56.2 (10.5)</td></tr><tr><td>Gender</td><td/><td/><td/></tr><tr><td>&#x000a0;Male</td><td>15 (58%)</td><td>24 (65%)</td><td>39 (62%)</td></tr><tr><td>&#x000a0;Female</td><td>11 (42%)</td><td>13 (35%)</td><td>24 (38%)</td></tr><tr><td>Race</td><td/><td/><td/></tr><tr><td>&#x000a0;Caucasian</td><td>24 (92%)</td><td>30 (81%)</td><td>54 (86%)</td></tr><tr><td>Malignancy</td><td/><td/><td/></tr><tr><td>&#x000a0;Myeloma</td><td>14 (54%)</td><td>1 (3%)</td><td>15 (24%)</td></tr><tr><td>&#x000a0;Lymphoma</td><td>10 (38%)</td><td>4 (11%)</td><td>14 (22%)</td></tr><tr><td>&#x000a0;Acute leukemia</td><td>0</td><td>19 (51%)</td><td>19 (30%)</td></tr><tr><td>Prior treatments</td><td/><td/><td/></tr><tr><td>&#x000a0;Chemotherapy exposure in months (mean (SD))</td><td>6.6 (5.2)</td><td>7.2 (10.2)</td><td>7.0 (8.5)</td></tr><tr><td>&#x000a0;Number of chemotherapy regimens (mean (SD))</td><td>1.9 (1.2)</td><td>2.4 (1.7)</td><td>2.2 (1.5)</td></tr><tr><td>&#x000a0;Number of chemotherapy cycles (mean (SD))</td><td>8.0 (5.2)</td><td>5.9 (5.0)</td><td>6.8 (5.1)</td></tr><tr><td>&#x000a0;Anthracycline</td><td>13 (50%)</td><td>22 (59%)</td><td>35 (56%)</td></tr><tr><td>&#x000a0;Nucleoside analogue</td><td>4 (15%)</td><td>22 (59%)</td><td>26 (41%)</td></tr><tr><td>&#x000a0;Lenalidomide or thalidomide</td><td>14 (54%)</td><td>2 (5%)</td><td>16 (25%)</td></tr><tr><td>&#x000a0;Bortezomib</td><td>12 (46%)</td><td>0</td><td>12 (19%)</td></tr><tr><td>Prior Autologous transplant</td><td>1 (4%)</td><td>4 (11%)</td><td>5 (8%)</td></tr><tr><td>Comorbidity score (HCT-CI) (mean (SD))</td><td>3.7 (2.8)</td><td>2.7 (2.0)</td><td>3.1 (2.4)</td></tr></tbody></table></table-wrap><table-wrap id="t0015" position="float"><label>Table 3</label><caption><p>Comparison of <italic>p16</italic><sup><italic>INK4a</italic></sup> expression levels in T cells isolated from fresh blood (symptom burden cohort (SB)) or frozen PBMCs (tissue procurement cohort (TP)). A Z score was calculated for samples in each cohort and the values of 20 samples shared between cohorts is shown (r<sup>2</sup>&#x000a0;=&#x000a0;0.6).</p></caption><alt-text id="al0050">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>p16_SB</th><th>p16_TP</th></tr></thead><tbody><tr><td>A101</td><td>1.83</td><td>0.34</td></tr><tr><td>A103</td><td>&#x02212;&#x000a0;1.34</td><td>&#x02212;&#x000a0;1.40</td></tr><tr><td>A108 6&#x000a0;months</td><td>&#x02212;&#x000a0;0.33</td><td>0.14</td></tr><tr><td>A108 BL</td><td>&#x02212;&#x000a0;0.74</td><td>&#x02212;&#x000a0;1.94</td></tr><tr><td>A109 6&#x000a0;months</td><td>0.44</td><td>0.68</td></tr><tr><td>A109 BL</td><td>&#x02212;&#x000a0;1.52</td><td>&#x02212;&#x000a0;1.04</td></tr><tr><td>A110</td><td>&#x02212;&#x000a0;1.59</td><td>&#x02212;&#x000a0;0.50</td></tr><tr><td>A202</td><td>&#x02212;&#x000a0;0.50</td><td>&#x02212;&#x000a0;0.96</td></tr><tr><td>A203</td><td>0.52</td><td>&#x02212;&#x000a0;0.05</td></tr><tr><td>A204</td><td>0.13</td><td>1.39</td></tr><tr><td>A208 6&#x000a0;months</td><td>1.55</td><td>1.90</td></tr><tr><td>A208 BL</td><td>&#x02212;&#x000a0;0.63</td><td>&#x02212;&#x000a0;1.17</td></tr><tr><td>B202 6&#x000a0;months</td><td>&#x02212;&#x000a0;0.39</td><td>0.65</td></tr><tr><td>B202 BL</td><td>&#x02212;&#x000a0;0.61</td><td>&#x02212;&#x000a0;0.54</td></tr><tr><td>B204</td><td>&#x02212;&#x000a0;1.32</td><td>&#x02212;&#x000a0;1.45</td></tr><tr><td>B205</td><td>0.06</td><td>&#x02212;&#x000a0;0.38</td></tr><tr><td>B206</td><td>0.94</td><td>2.05</td></tr><tr><td>B209</td><td>&#x02212;&#x000a0;0.63</td><td>&#x02212;&#x000a0;0.26</td></tr><tr><td>B211</td><td>1.61</td><td>1.27</td></tr><tr><td>B212</td><td>&#x02212;&#x000a0;0.11</td><td>&#x02212;&#x000a0;0.28</td></tr></tbody></table></table-wrap><table-wrap id="t0020" position="float"><label>Table 4</label><caption><p>Pre-transplant <italic>p16</italic><sup><italic>INK4a</italic></sup> expression is associated with amount and type of pre-transplant chemotherapy and history of prior autologous transplant in univariate analysis. Linear regression analysis (A) and one-way analysis of variance (B) demonstrate association of <italic>p16</italic><sup><italic>INK4a</italic></sup> with patient's characteristics and therapies.</p></caption><alt-text id="al0055">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="5">A<hr/></th></tr><tr><th rowspan="2">Baseline characteristic</th><th colspan="2">Autologous HSCT (N&#x000a0;=&#x000a0;26)<hr/></th><th colspan="2">Allogeneic HSCT (N&#x000a0;=&#x000a0;37)<hr/></th></tr><tr><th>Estimate (log 2)</th><th>p-Value</th><th>Estimate (log 2)</th><th>p-Value</th></tr></thead><tbody><tr><td>Age</td><td>&#x02212;&#x000a0;0.002</td><td>0.94</td><td>0.001</td><td>0.92</td></tr><tr><td>Comorbidity score (HCT-CI)</td><td>&#x02212;&#x000a0;0.081</td><td>0.18</td><td>&#x02212;&#x000a0;0.40</td><td>0.60</td></tr><tr><td>Number of cycles of chemotherapy</td><td>0.014</td><td>0.68</td><td><bold>0.086</bold></td><td><bold>0.003</bold></td></tr><tr><td colspan="5">&#x02028;&#x02028;</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="5">B<hr/></th></tr><tr><th rowspan="2">Baseline characteristic</th><th colspan="2">Autologous HSCT (N&#x000a0;=&#x000a0;26)<hr/></th><th colspan="2">Allogeneic HSCT (N&#x000a0;=&#x000a0;37)<hr/></th></tr><tr><th>Difference (log 2)</th><th>p-Value</th><th>Difference (log 2)</th><th>p-Value</th></tr></thead><tbody><tr><td>Prior autologous transplant</td><td>NA</td><td>NA</td><td><bold>1.22</bold></td><td><bold>0.01</bold></td></tr><tr><td>Exposure to alkylator &#x02013; incl prior auto</td><td>0.20</td><td>0.56</td><td><bold>0.91</bold></td><td><bold>0.01</bold></td></tr><tr><td>Exposure to alkylator &#x02013; not incl prior auto</td><td>0.19</td><td>0.6</td><td>0.62</td><td>0.13</td></tr><tr><td>Exposure to anthracycline</td><td>0.28</td><td>0.41</td><td>&#x02212;&#x000a0;0.04</td><td>0.91</td></tr><tr><td>Exposure to nucleoside analogue</td><td>0.70</td><td>0.13</td><td>&#x02212;&#x000a0;0.23</td><td>0.45</td></tr><tr><td>Exposure to lenalidomide or thalidomide</td><td>&#x02212;&#x000a0;0.04</td><td>0.91</td><td>0.75</td><td>0.26</td></tr><tr><td>Exposure to bortezomib</td><td>0.05</td><td>0.88</td><td>NA</td><td>NA</td></tr></tbody></table></table-wrap><table-wrap id="t0025" position="float"><label>Table 5</label><caption><p>High-dose chemotherapy increases <italic>p16</italic><sup><italic>INK4a</italic></sup> expression. Changes in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression between baseline and follow-up in aggregated cohort in autologous-HSCT, allogeneic-HSCT or breast cancer patients.</p></caption><alt-text id="al0060">Table 5</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Treatment type</th><th>Pre-treatment log2p16</th><th>Post-treatment log2p16</th><th>Change in <italic>p16</italic><sup><italic>INK4a</italic></sup> expression</th><th>P-value</th></tr></thead><tbody><tr><td>Autologous HSCT (mean (95% CI)); N&#x000a0;=&#x000a0;6</td><td>&#x02212;&#x000a0;0.88 (&#x02212;&#x000a0;1.44, &#x02212;&#x000a0;0.32)</td><td>0.73 (0.20, 1.27)</td><td>3.05</td><td>0.002</td></tr><tr><td>Allogeneic HSCT (mean (95% CI)); N&#x000a0;=&#x000a0;21</td><td>&#x02212;&#x000a0;0.13 (&#x02212;&#x000a0;0.53, 0.27)</td><td>0.82 (0.53, 1.11)</td><td>1.93</td><td>0.0004</td></tr><tr><td>Adjuvant breast cancer (mean (95% CI); N&#x000a0;=&#x000a0;24</td><td>&#x02212;&#x000a0;0.48 (&#x02212;&#x000a0;0.12, &#x02212;&#x000a0;0.83)</td><td>0.48 (0.22, 0.74)</td><td>1.93</td><td>0.0001</td></tr></tbody></table></table-wrap></floats-group></article>